Elanco Animal Health Incorporated Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO Mr. Jeffrey Simmons; PEO total compensation $14.93M; PEO compensation actually paid $37.81M; Other NEO average total compensation $3.83M.
- 2024-12-31: PEO total compensation $14.83M; PEO compensation actually paid $9.23M; Other NEO average total compensation $3.37M.
- 2023-12-31: PEO total compensation $13.66M; PEO compensation actually paid $17.32M; Other NEO average total compensation $3.03M.
- 2022-12-31: PEO total compensation $12.71M; PEO compensation actually paid -$2.02M; Other NEO average total compensation $2.78M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Mr. Jeffrey Simmons | $14.93M | $37.81M | $3.83M | $5.38M | $74.00 | $188.00 | -$232.00M | Adjusted EBITDA $901.00M | 2026-04-08 |
| 2024-12-31 | $14.83M | $9.23M | $3.37M | $2.40M | $39.00 | $148.00 | $338.00M | $910.00M | 2026-04-08 | |
| 2023-12-31 | $13.66M | $17.32M | $3.03M | $3.57M | $49.00 | $137.00 | -$1.23B | $979.00M | 2026-04-08 | |
| 2022-12-31 | $12.71M | -$2.02M | $2.78M | $863.89K | $40.00 | $136.00 | -$78.00M | $1.02B | 2026-04-08 | |
| 2021-12-31 | $12.06M | $16.53M | $3.20M | $3.75M | $93.00 | $126.00 | -$483.00M | $1.06B | 2026-04-08 | |
| 2024-12-31 | Mr. Jeffrey Simmons | $14.83M | $9.23M | $3.37M | $2.40M | $41.00 | $159.00 | $338.00M | Adjusted EBITDA $910.00M | 2025-03-27 |
| 2023-12-31 | $13.66M | $17.32M | $3.03M | $3.57M | $51.00 | $147.00 | -$1.23B | $979.00M | 2025-03-27 | |
| 2022-12-31 | $12.71M | -$2.02M | $2.78M | $863.89K | $41.00 | $147.00 | -$78.00M | $1.02B | 2025-03-27 | |
| 2021-12-31 | $12.06M | $16.53M | $3.20M | $3.75M | $96.00 | $135.00 | -$483.00M | $1.06B | 2025-03-27 | |
| 2020-12-31 | $8.96M | $9.32M | $2.15M | $2.18M | $104.00 | $108.00 | -$574.00M | $529.00M | 2025-03-27 | |
| 2023-12-31 | Mr. Jeffrey Simmons | $13.66M | $17.32M | $3.03M | $3.57M | $51.00 | $137.00 | -$1.23B | Adjusted EBITDA $979.00M | 2024-04-19 |
| 2022-12-31 | Mr. Jeffrey Simmons | $12.71M | -$2.02M | $2.78M | $863.89K | $41.00 | $136.00 | -$78.00M | $1.02B | 2024-04-19 |
| 2021-12-31 | Mr. Jeffrey Simmons | $12.06M | $16.53M | $3.20M | $3.75M | $96.00 | $126.00 | -$483.00M | $1.06B | 2024-04-19 |
| 2020-12-31 | Mr. Jeffrey Simmons | $8.96M | $9.32M | $2.15M | $2.18M | $104.00 | $108.00 | -$574.00M | $529.00M | 2024-04-19 |
| 2022-12-31 | Mr. Jeffrey Simmons | $12.71M | -$2.02M | $2.78M | $863.89K | $41.00 | $126.00 | -$78.00M | Adjusted Net Income $544.00M | 2023-04-06 |
| 2021-12-31 | Mr. Jeffrey Simmons | $12.06M | $16.53M | $3.20M | $3.75M | $96.00 | $149.00 | -$483.00M | $522.00M | 2023-04-06 |
| 2020-12-31 | Mr. Jeffrey Simmons | $8.96M | $9.32M | $2.15M | $2.18M | $104.00 | $132.00 | -$574.00M | $199.00M | 2023-04-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |